Breast Clinical Trial
(Double Blind Placebo Controlled)
60 were enrolled, with an initial diagnoses of moderate to severe Stage I to Stage IV, Malignant Carcinoma in the Breast Tissue. Each diagnoses was confirmed by a Fine Needle Aspiration Biopsy (FNAB) or Breast Biopsy (BB), and an MRI. Participants were randomly assigned to one of three groups. The first group took ReaLife+TM. The second took a placebo. The third took nothing. No patient received surgery, chemo or radiation before or during the Clinical Trial. Each Patient in Group 1, took 1 packet of ReaLife+TM twice daily, mixed with water or juice.